HOME Top Market Reports Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012 – 2017) - (Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases)

Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012 – 2017) - (Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases)

By: marketsandmarkets.com
Publishing Date: October 2012
Report Code: PH 1300

Discount on Reports  

Enquiry Before Buying
 
purchase report
download pdf  request for customisation


This research report titled “Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017)” provides details about various autologous cell based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are Safer, Affordable, Robust, Rapid, Easy to use, Effective and Deliverable to the end user. Autologous stem cell transplantation for particular application areas is safe experiencing robust growth and has minimal steps of procedure to follow and is rapid in deriving the results. The sources for autologous stem cell therapy are Mesenchymal stem cells, Hematopoietic stem cells, Chondrocytes and so on. Currently, the cost of the treatments is not affordable however, by the intrusion of government bodies, this mode of treatment will certainly experience an immense market growth.

The report gives a detailed analysis about state of the art of both autologous stem cell and non-stem cell treatments. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company and revenue forecast. It includes latest autologous cultured cell treatment details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges, the market revenue is forecasted for a period of five years, i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information on potential application areas for investments.

Autologous Stem Cell Therapy technology (a form of regenerative cell therapy) is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.

TABLE OF CONTENTS:

1 INTRODUCTION
  1.1 KEY TAKE AWAYS
  1.2 REPORT SCOPE
  1.3 RESEARCH METHODOLOGY
  1.4 KEY DATA SOURCES

2 EXECUTIVE SUMMARY

3 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY -TECHNOLOGY LANDSCAPE ANALYSIS
  3.1 AUTOLOGOUS CELL THERAPY TECHNOLOGY
      3.1.1 AUTOLOGOUS CELL TECHNOLOGY OVERVIEW
      3.1.2 AUTOLOGOUS CELL TECHNOLOGY PROCESS
      3.1.3 APPLICATION AREAS
            3.1.3.1 NEURODEGENERATIVE DISEASES
            3.1.3.2 CARDIOVASCULAR DISEASES
            3.1.3.3 CANCER AND AUTOIMMUNE DISEASES
            3.1.3.4 SKIN TRANSPLANTATION
            3.1.3.5 INFECTIOUS DIESEASE
  3.2 TECHNOLOGY TREND ANALYSIS
  3.3 VALUE CHAIN ANALYSIS

4 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY TECHNOLOGY INVESTMENT POTENTIAL
  4.1 INVESTMENT CLIMATE ASSESSMENT
      4.1.1 INVESTOR NETWORKS
            4.1.1.1 PUBLIC FUNDING BODIES
            4.1.1.2 FUNDING/GRANTS FROM NGO ORGANIZATIONS
            4.1.1.3 PRIVATE INVESTORS AND VENTURE CAPITAL FIRMS
            4.1.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS
            4.1.1.5 INVESTOR INCLINATION AND PATTERNS
  4.2 INVESTMENT OPPURTUNITIES
      4.2.1 LICENSING AND ACQUISITION
      4.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT

5 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY MARKET LANDSCAPE ANALYSIS
  5.1 AUTOLOGOUS VS ALLOGENIC – MARKET LANDSCAPE
  5.2 GLOBAL MARKET FORECAST
  5.3 MARKET DYNAMICS
      5.3.1 DRIVERS
      5.3.2 RESTRAINTS
      5.3.3 CHALLENGES
      5.3.4 DEMAND SIDE ANALYSIS

6 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY
  6.1 INTRODUCTION
  6.2 US, CANADA, LATIN AMERICA
  6.3 UK, GERMANY, FRANCE
  6.4 AUSTRALIA, KOREA, JAPAN, ROW
  6.5 REGIONS WITH HIGH TECHNOLOGY ADOPTION

7 COMPETITIVE LANDSCAPE
  7.1 MERGERS AND ACQUISITIONS
  7.2 PARTNERSHIPS AND COLLABORATIONS
  7.3 NEW PRODUCT DEVELOPMENT INITIATIVES (THOSE IN PIPELINE)

8 PATENT ANALYSIS

9 TECHNOLOGY ANALYSIS AND ROAD MAPPING
  9.1 INTRODUCTION
  9.2 CLINICAL TRIALS DETAILS – MEDICAL CENTERS AND UNIVERSITIES
  9.3 DATA PERTAINING TO AUTOLOGOUS CELL THERAPY CLINICAL TRIALS

10 ANALYST INSIGHTS AND RECOMMENDATIONS

11 COMPANY PROFILES
   11.1 ANTRIA (CRO) (U.S.)
   11.2 BIOHEART (U.S.)
   11.3 BRAINSTORM CELL THERAPEUTICS (U.S.)
   11.4 CYTORI (U.S.)
   11.5 DENDREON CORPORATION (U.S.)
   11.6 FIBROCELL (U.S.)
   11.7 GENESIS BIOPHARMA (U.S.)
   11.8 GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.)
   11.9 NEOSTEM (U.S.)
   11.10 OPEXA THERAPEUTICS (U.S.)
   11.11 ORGENESIS (U.S.)
   11.12 REGENEXX (U.S.)
   11.13 REGENEUS (AUSTRALIA)
   11.14 TENGION (U.S.)
   11.15 TIGENIX (BELGIUM)
   11.16 VIRXSYS (U.S.)

12 APPENDIX

13 GLOSSARY
 

LIST OF TABLES

TABLE 1  FUNDING DETAILS IN EUROPE
TABLE 2 LICENSING & ACQUISITION
TABLE 3 DATA PERTAINING TO DISEASES - DISEASE INCIDENCE & TREATMENT COSTS
TABLE 4 DRIVERS
TABLE 5 RESTRAINTS
TABLE 6 U.S. FDA GUIDANCE DOCUMENTS
TABLE 7 MERGERS & ACQUISITIONS
TABLE 8 PARTNERSHIPS & COLLABORATIONS 
TABLE 9 NEW PRODUCT DEVELOPMENT INITIATIVES (THOSE IN-PIPELINE)
TABLE 10 CLINICAL TRIALS DETAILS – MEDICAL CENTERS & UNIVERSITIES 
TABLE 11 KEY PATENTS 
TABLE 12 NEW PRODUCT DEVELOPMENT INITIATIVES (IN-PIPELINE)
 

LIST OF FIGURES

FIGURE 1 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY MARKET REVENUE FORECAST
FIGURE 2 SEGMENTATION OF CELL THERAPY
FIGURE 3 ACT MARKET REVENUE FORECAST
FIGURE 4 PERCENTAGE OF SHAREHOLDERS IN THE AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY
FIGURE 5 INVESTOR NETWORKS
FIGURE 6 NIH FUNDING IN USA FOR AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY IN 2010
FIGURE 7 OPPORTUNITY STRATEGIC EVALUATION ANALYSIS
FIGURE 8 MARKET REVENUE OF AUTOLOGOUS VS ALLOGENIC CELL THERAPY PRODUCTS (2011)
FIGURE 9 MARKET SHARE OF AUTOLOGOUS VS ALLOGENIC CELL THERAPY PRODUCTS (2011)
FIGURE 10 SEGMENTATION OF CELL THERAPY TREATMENT
FIGURE 11 SEGMENTATION BY APPLICATION AREAS
FIGURE 12 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY MARKET REVENUE FORECAST, 2012 - 2017 ($MILLION)
FIGURE 13 MARKET SHARE (%) AND REVENUES ($MILLIONS) BY REGION (2012)
FIGURE 14 MARKET SHARE (%) AND REVENUES ($MILLIONS) BY REGION (2017)
FIGURE 15 MARKET SHARE (%) AND REVENUES ($MILLIONS) BY APPLICATIONS (2012)
FIGURE 16 MARKET SHARE (%) AND REVENUES ($MILLIONS) BY APPLICATIONS (2017)
FIGURE 17 NUMBER OF M&A'S IN ACT TECHNOLOGY
FIGURE 18 GEOGRAPHICAL AUTOLOGOUS TECHNOLOGIES/ PRODUCT-PATENT DISTRIBUTION
FIGURE 19 REGIONAL DATA OF CLINICAL TRIALS OF THE TECHNOLOGY
FIGURE 20 CLINICAL TRIALS BY INDICATION
FIGURE 21 STEM CELL TYPES EMPLOYED IN INTERVENTIONAL CLINICAL TRIALS
FIGURE 22 SOURCE OF MESENCHYMAL STEM CELLS (MSCS)
FIGURE 23 ONGOING CLINICAL TRIALS
FIGURE 24 NUMBER OF CELL THERAPY CLINICAL TRIALS BY REGION
FIGURE 25 NUMBER OF CELL THERAPY CLINICAL TRIALS BY COUNTRY
FIGURE 26 NUMBER OF PUBMED PUBLICATIONS
FIGURE 27 COUNTRY WISE PUBLICATION DETAILS

Autologous Stem Cell and Non-Stem Cell Based Therapies is a novel therapeutic platform growing rapidly in the field of regenerative medicine. It is considered to be an effective and safer technology in comparison with the existing transplant technologies such as allogeneic and xeno transplants. Autologous transplants facilitates in reduction of risks associated with bio-incompatibility, disease transmission and immunological reactions. Autologous Stem Cell and Non-Stem Cell Based Therapies market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.

Hence this technology is expected to provide immense investment opportunities in the global market.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Revenue Forecast

Autologous Cell Therapy Market, ACT Market

Source: MarketsandMarkets Analysis

In this report, Autologous Cell Therapy is primarily segmented as stem cell and non-stem cell based therapies. Stem cells have the potential to develop into many types of cells in the body during the early stage of life and also serve as an internal repairing system; therefore the number of treatments based on stem cells is comparatively higher than non-stem cells. This report explains the potential therapeutic areas of ACT such as Neurodegenerative, Cardiovascular, Cancer and Autoimmune diseases, Skin transplantation and Infectious diseases. It gives detailed information about current advances and applications of Autologous Cell Therapy technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It explains the principle of the therapeutic products of various companies working in this sector.

  • Autologous Stem Cell and Non-Stem Cell Based treatments in North America are rapidly emerging as a major treatment for various incurable diseases such as Myocardial infarction, ischemic heart failure and diabetes.
  • In Brazil and Mexico, treatments through Autologous Stem Cell and Non-Stem Cell Based Therapies for various diseases like diabetes and skin transplantation are actively progressing.
  • In Europe, countries such as U.K., Germany and France are actively developing the Autologous Stem Cell and Non-Stem Cell Based Therapies technology for various diseases.
  • Treatment for osteoarthritis through Chondrocelect has got the reimbursement option.
  • In countries such as Australia, Korea, Japan and other developing nations of Asia pacific, huge investments are being for developing the Autologous Stem Cell and Non-Stem Cell Based Therapies treatments for various incurable diseases. Recently RNL Bio, Korean company has been providing stem cell treatments for patients in Korea and Turkey.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports